ES2525477T3 - Anticuerpos anti-factor D humanizados - Google Patents

Anticuerpos anti-factor D humanizados Download PDF

Info

Publication number
ES2525477T3
ES2525477T3 ES07868632.6T ES07868632T ES2525477T3 ES 2525477 T3 ES2525477 T3 ES 2525477T3 ES 07868632 T ES07868632 T ES 07868632T ES 2525477 T3 ES2525477 T3 ES 2525477T3
Authority
ES
Spain
Prior art keywords
seq
identity
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07868632.6T
Other languages
English (en)
Spanish (es)
Inventor
Herren Wu
Sanjaya Singh
Sek Chung Fung
Ling-Ling An
Henry B. Lowman
Robert F. Kelley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39345075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525477(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2525477T3 publication Critical patent/ES2525477T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21046—Complement factor D (3.4.21.46)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
ES07868632.6T 2006-11-02 2007-10-31 Anticuerpos anti-factor D humanizados Active ES2525477T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85650506P 2006-11-02 2006-11-02
US856505P 2006-11-02
PCT/US2007/083172 WO2008055206A2 (en) 2006-11-02 2007-10-31 Humanized anti-factor d antibodies

Publications (1)

Publication Number Publication Date
ES2525477T3 true ES2525477T3 (es) 2014-12-23

Family

ID=39345075

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07868632.6T Active ES2525477T3 (es) 2006-11-02 2007-10-31 Anticuerpos anti-factor D humanizados
ES15151317T Active ES2700609T3 (es) 2006-11-02 2007-10-31 Anticuerpos anti-factor D humanizados y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15151317T Active ES2700609T3 (es) 2006-11-02 2007-10-31 Anticuerpos anti-factor D humanizados y sus usos

Country Status (35)

Country Link
US (10) US8067002B2 (enExample)
EP (4) EP2907827B1 (enExample)
JP (6) JP2010508819A (enExample)
KR (6) KR20170110727A (enExample)
CN (7) CN106188303A (enExample)
AR (2) AR063760A1 (enExample)
AU (1) AU2007313685C1 (enExample)
BR (1) BRPI0716299A2 (enExample)
CA (2) CA2667997C (enExample)
CL (1) CL2007003161A1 (enExample)
CO (1) CO6190543A2 (enExample)
CR (1) CR10827A (enExample)
DK (2) DK2907827T3 (enExample)
EC (1) ECSP099379A (enExample)
ES (2) ES2525477T3 (enExample)
HK (2) HK1215712A1 (enExample)
HR (1) HRP20181969T1 (enExample)
IL (3) IL198512A (enExample)
LT (1) LT2907827T (enExample)
MA (1) MA30962B1 (enExample)
MX (1) MX2009004665A (enExample)
MY (2) MY183804A (enExample)
NO (1) NO20092121L (enExample)
NZ (3) NZ609813A (enExample)
PE (2) PE20121034A1 (enExample)
PH (1) PH12015501763A1 (enExample)
PL (2) PL2907827T3 (enExample)
PT (2) PT2907827T (enExample)
RS (1) RS58233B1 (enExample)
RU (3) RU2474589C9 (enExample)
SI (2) SI2097455T1 (enExample)
TW (5) TWI472535B (enExample)
UA (2) UA101603C2 (enExample)
WO (1) WO2008055206A2 (enExample)
ZA (2) ZA200903088B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
EP2826788B1 (en) 2006-06-21 2017-12-13 MUSC Foundation for Research Development Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules
AU2007313685C1 (en) 2006-11-02 2015-09-17 Genentech, Inc. Humanized anti-Factor D antibodies
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2899209A1 (en) * 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP2297208A4 (en) * 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BRPI0913406A2 (pt) * 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
WO2010028028A1 (en) 2008-09-08 2010-03-11 Virginia Tech Intellectual Properties Systems, devices, and methods for managing energy usage
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110020642A (ko) 2009-08-24 2011-03-03 삼성전자주식회사 사용자 접근을 인식하여 반응하는 ｇｕｉ제공 장치 및 방법
RU2012112550A (ru) * 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
US8716450B2 (en) * 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32949A (es) * 2009-10-15 2011-02-28 Abbott Lab Proteínas de unión a il-1
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
US10239937B2 (en) 2009-11-05 2019-03-26 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
TW201206473A (en) * 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130133247A (ko) 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
KR20150036481A (ko) 2012-07-12 2015-04-07 노파르티스 아게 보체 경로 조절제 및 그의 용도
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
WO2014047311A1 (en) 2012-09-19 2014-03-27 Genentech, Inc. Methods and compositions for preventing norleucine misincorporation into proteins
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
RU2750285C2 (ru) 2015-10-30 2021-06-25 Дженентек, Инк. АНТИТЕЛА ПРОТИВ НtrА1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2017075170A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Methods of measuring factor d activity and potency of factor d inhibitors
CN108602881A (zh) * 2015-10-30 2018-09-28 豪夫迈·罗氏有限公司 抗-因子d抗体制剂
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP2019506159A (ja) 2016-01-20 2019-03-07 ヴィトリサ セラピューティクス， インコーポレイテッド Ｄ因子を阻害するための組成物および方法
MX393066B (es) 2016-04-18 2025-03-24 Celldex Therapeutics Inc Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
WO2017219995A1 (zh) 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
JP2020507581A (ja) 2017-02-10 2020-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗ｄ因子抗体及びその使用
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华（上海）生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
FR3071483B1 (fr) * 2017-09-27 2020-11-27 Airbus Operations Sas Systeme de surveillance de braquage d'une roulette de train d'atterrissage d'un aeronef
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
CN110240652B (zh) * 2019-06-05 2022-09-06 百奥泰生物制药股份有限公司 抗补体d因子抗体及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2024515066A (ja) * 2021-04-09 2024-04-04 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站（陕西省血液中心） 一种中和抗d抗体的抗独特型抗体及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE161192T1 (de) 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
ES2236706T3 (es) 1994-03-23 2005-07-16 Alexion Pharmaceuticals, Inc. Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5897475A (en) 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
ES2270530T3 (es) 1997-08-26 2007-04-01 Amgen Fremont Inc. Un procedimiento para inhibir la activacion del completo por la via alternativa.
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
JP2002502589A (ja) 1998-02-09 2002-01-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４５個のヒト分泌タンパク質
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
ATE412431T1 (de) 1998-02-20 2008-11-15 Tanox Inc Inhibitoren der komplement-aktivierung
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
EP1108019A2 (en) 1998-08-27 2001-06-20 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468977B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
DK1484338T3 (da) 1998-12-22 2007-06-11 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
JP2004516227A (ja) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
RU2244748C2 (ru) 1999-03-11 2005-01-20 РМФ Диктажен С.А. Адгезивные молекулы сосудов и модуляция их функций
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
PT1265929E (pt) * 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
EP2026073B1 (en) 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
EP1326897A2 (en) 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
AU2002331601B2 (en) 2001-08-17 2006-04-13 Tanox, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
AU2005314461B2 (en) 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP2377951A1 (en) 2005-02-14 2011-10-19 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
FI118793B (fi) * 2005-07-11 2008-03-31 Olli Friman Rullaluistimen pyörän vierintälaakerin suojalevy
CN105582523B (zh) 2005-10-08 2022-04-15 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US7941135B2 (en) 2006-03-22 2011-05-10 Alcatel-Lucent Usa Inc. Methods of performing live monitoring of a wireless communication network
AU2007313685C1 (en) 2006-11-02 2015-09-17 Genentech, Inc. Humanized anti-Factor D antibodies
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
SI2097455T1 (sl) 2015-03-31
KR20150046389A (ko) 2015-04-29
CO6190543A2 (es) 2010-08-19
AU2007313685C1 (en) 2015-09-17
CA2667997C (en) 2016-10-11
JP2013027404A (ja) 2013-02-07
US20150376295A1 (en) 2015-12-31
ZA201300949B (en) 2016-05-25
TW201211063A (en) 2012-03-16
US20160002353A1 (en) 2016-01-07
ECSP099379A (es) 2009-07-31
WO2008055206A9 (en) 2008-07-17
US8187604B2 (en) 2012-05-29
RS58233B1 (sr) 2019-03-29
RU2012147286A (ru) 2014-05-20
CA2667997A1 (en) 2008-05-08
LT2907827T (lt) 2018-12-10
JP2013017490A (ja) 2013-01-31
KR20160092061A (ko) 2016-08-03
MY157948A (en) 2016-08-30
HRP20181969T1 (hr) 2019-02-08
JP2010508819A (ja) 2010-03-25
KR20140101873A (ko) 2014-08-20
UA116614C2 (uk) 2018-04-25
HK1213920A1 (en) 2016-07-15
EP2097455B1 (en) 2014-10-22
IL198512A (en) 2015-05-31
TW200827373A (en) 2008-07-01
PH12015501763A1 (en) 2019-04-29
EP2097455A2 (en) 2009-09-09
JP2015214591A (ja) 2015-12-03
JP2017200492A (ja) 2017-11-09
CN105085682A (zh) 2015-11-25
RU2009120699A (ru) 2010-12-10
RU2474589C9 (ru) 2019-08-15
KR20090078364A (ko) 2009-07-17
RU2474589C2 (ru) 2013-02-10
AU2007313685A1 (en) 2008-05-08
US8193329B2 (en) 2012-06-05
UA101603C2 (ru) 2013-04-25
US20110165622A1 (en) 2011-07-07
TWI472535B (zh) 2015-02-11
PL2097455T3 (pl) 2015-04-30
US20170166630A1 (en) 2017-06-15
HK1215712A1 (zh) 2016-09-09
JP5918794B2 (ja) 2016-05-18
KR20190003860A (ko) 2019-01-09
AU2007313685B2 (en) 2013-01-24
NZ576812A (en) 2011-11-25
EP2471818A1 (en) 2012-07-04
US8372403B2 (en) 2013-02-12
TW201843170A (zh) 2018-12-16
IL254137A0 (en) 2017-10-31
HK1226417A1 (zh) 2017-09-29
CN106188299A (zh) 2016-12-07
JP2014110810A (ja) 2014-06-19
EP2907827B1 (en) 2018-09-19
CN101589063B (zh) 2016-08-31
JP5474158B2 (ja) 2014-04-16
CN106188304A (zh) 2016-12-07
CL2007003161A1 (es) 2008-05-30
AU2007313685A8 (en) 2009-06-18
US20140303355A1 (en) 2014-10-09
BRPI0716299A2 (pt) 2013-08-13
US20160002352A1 (en) 2016-01-07
PE20081259A1 (es) 2008-10-31
ZA200903088B (en) 2013-05-29
PT2097455E (pt) 2015-02-05
US20120230985A1 (en) 2012-09-13
US8753826B2 (en) 2014-06-17
WO2008055206A2 (en) 2008-05-08
AR100225A2 (es) 2016-09-21
TW201534620A (zh) 2015-09-16
EP2907827A1 (en) 2015-08-19
PT2907827T (pt) 2018-12-04
TW201716437A (zh) 2017-05-16
US8067002B2 (en) 2011-11-29
MA30962B1 (fr) 2009-12-01
PE20121034A1 (es) 2012-08-25
US20080118506A1 (en) 2008-05-22
CN106084055A (zh) 2016-11-09
NZ596042A (en) 2013-06-28
PL2907827T3 (pl) 2019-03-29
NO20092121L (no) 2009-07-24
HK1138018A1 (zh) 2010-08-13
IL198512A0 (en) 2011-08-01
CN106188303A (zh) 2016-12-07
IL238517B (en) 2018-05-31
DK2907827T3 (da) 2019-01-02
NZ609813A (en) 2015-01-30
CA2939806A1 (en) 2008-05-08
KR20170110727A (ko) 2017-10-11
EP3466971A1 (en) 2019-04-10
TWI391401B (zh) 2013-04-01
IL238517A0 (en) 2015-06-30
SI2907827T1 (sl) 2019-02-28
MY183804A (en) 2021-03-16
RU2678802C2 (ru) 2019-02-01
DK2097455T3 (en) 2014-12-15
AR063760A1 (es) 2009-02-18
KR101645144B1 (ko) 2016-08-03
CR10827A (es) 2009-09-07
RU2019102393A (ru) 2020-07-29
CN106084054A (zh) 2016-11-09
CN101589063A (zh) 2009-11-25
US20130171070A1 (en) 2013-07-04
WO2008055206A3 (en) 2008-09-04
ES2700609T3 (es) 2019-02-18
US20110123528A1 (en) 2011-05-26
MX2009004665A (es) 2009-06-18

Similar Documents

Publication Publication Date Title
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
ES2533242T3 (es) Prevención y tratamiento de afecciones oculares asociadas con el complemento
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
CO6700829A2 (es) Moduladores novedosos y métodos de uso
ES2684475T3 (es) Proteínas que se unen a beta amiloide
AR083747A1 (es) Anticuerpos anti-il-23
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
NZ596295A (en) Anti-5T4 antibodies and uses thereof
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
CL2012000518A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07).
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
AR054474A1 (es) Formulacion de anticuerpos estables
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
CO6231000A2 (es) Anticuerpos contra de erbb3 y usos de los mismos
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)